Plk shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

Plk shRNA Plasmid (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
Plk shRNA Plasmid (h)

Product Specs
ItemPlk shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-36277-SH
Quantity20 µg
TypeshRNA Plasmid
Specieshuman
NCBI Full Gene Namepolo like kinase 1
NCBI Gene AliasesPLK, STPK13
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Ste20-like Kinase-mediated Control of Actin Polymerization Is a New Mechanism for Thin Filament-associated Regulation of Airway Smooth Muscle ContractionAmerican journal of respiratory cell and molecular biologyMay 1, 2020Wang Y, Wang R, Tang DD.

(2) Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 ExpressionCancersJanuary 23, 2020Lee J, Lee J, Sim W, Kim JH.

(3) Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic LeukemiaMolecular cancer therapeuticsSeptember 1, 2019Kannan S, Aitken MJL, Herbrich SM, Golfman LS, Hall MG, Mak DH, Burks JK, Song G, Konopleva M, Mullighan CG, et al.

(4) Plk1 Mediates Paxillin Phosphorylation (Ser-272), Centrosome Maturation, and Airway Smooth Muscle Layer Thickening in Allergic AsthmaScientific reportsMay 17, 2019Rezey AC, Gerlach BD, Wang R, Liao G, Tang DD.

(5) Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP ExpressionInternational journal of molecular sciencesNovember 29, 2017Jeon MY, Min KJ, Woo SM, Seo SU, Kim S, Park JW, Kwon TK.

(6) Polo-like Kinase 1 Regulates Vimentin Phosphorylation at Ser-56 and Contraction in Smooth MuscleThe Journal of biological chemistryNovember 4, 2016Li J, Wang R, Gannon OJ, Rezey AC, Jiang S, Gerlach BD, Liao G, Tang DD.

(7) Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cellsOncotargetAugust 21, 2015Okabe S, Tauchi T, Tanaka Y, Sakuta J, Ohyashiki K.

(8) Plk1 regulates MEK1/2 and proliferation in airway smooth muscle cellsRespiratory researchAugust 5, 2015Jiang S, Tang DD.

(9) Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosisOncology reportsMarch 1, 2015Zhang R, Shi H, Ren F, Liu H, Zhang M, Deng Y, Li X.

(10) Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppressionCell cycle (Georgetown, Tex.)January 1, 2015Nair JS, Schwartz GK.

(11) Polo-like kinase 1 (PLK1) is involved in toll-like receptor (TLR)-mediated TNF-α production in monocytic THP-1 cellsPloS oneJanuary 1, 2013Hu J, Wang G, Liu X, Zhou L, Jiang M, Yang L.

(12) MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1BMC cancerNovember 14, 2012Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX.

(13) A novel treatment strategy targeting polo-like kinase 1 in hematological malignanciesLeukemiaSeptember 1, 2009Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, Koeffler HP, Yokoyama A.

(14) Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinomaClinical cancer research : an official journal of the American Association for Cancer ResearchNovember 1, 2008Wang XQ, Zhu YQ, Lui KS, Cai Q, Lu P, Poon RT.

Be the First to Write a Review!